Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Xie, Li ^a   Wei, Ling ^a   Song, Bao ^a   Wang, Xingwu ^a   Lv, Liyan ^a   Song, Xianrang ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; ESOPHAGUS CANCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; DRUG EFFECT; DRUG RESISTANCE; ESOPHAGUS TUMOR; PATHOLOGY; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; X RAY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE FRACTIONATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; FLUOROURACIL; HUMANS; PACLITAXEL; RADIATION TOLERANCE; TUMOR CELLS, CULTURED; X-RAYS;

EID: 67949095852     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-68     Document Type: Article

References (26)

1. The current management of esophageal cancer. S Law J Wong, Adv Surg 2007 41 93 119 10.1016/j.yasu.2007.05.007 17972559
2. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 2 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
3. Esophagus cancer. JF Seitz L Dahan J Jacob P Artru P Maingon L Bedenne JP Triboulet, Gastroenterol Clin Biol 2006 30 Spec No 2 2S5 2S15 17151558 (Pubitemid 46069186)
4. Esophageal cancer. PC Enzinger RJ Mayer, N Engl J Med 2003 349 23 2241 2252 10.1056/NEJMra035010 14657432
5. Esophageal cancer surgery in 2005. CD Wright, Minerva Chir 2005 60 6 431 444 16401998 (Pubitemid 43318304)
6. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. ZF Xiao ZY Yang J Liang YJ Miao M Wang WB Yin XZ Gu DC Zhang RG Zhang LJ Wang, Ann Thorac Surg 2003 75 2 331 336 10.1016/S0003-4975(02) 04401-6 12607634
7. Esophageal cancer: adjuvant therapy. GY Ku DH Ilson, Cancer J 2007 13 3 162 167 10.1097/PPO.0b013e318074dbe7 17620765
8. Treatment of localized esophageal cancer. B Brenner DH Ilson BD Minsky, Semin Oncol 2004 31 4 554 565 10.1053/j.seminoncol.2004.04.015 15297946
9. Preoperative therapy in esophageal cancer. GY Ku DH Ilson, Clin Adv Hematol Oncol 2008 6 5 371 379 18516027
10. Radiochemotherapy of esophageal cancer. Z Liao JD Cox R Komaki, J Thorac Oncol 2007 2 6 553 568 10.1097/01.JTO.0000275339.62831.5e 17545853
11. Multimodality treatment of esophageal cancer: a review of the current status and future directions. T Ng T Dipetrillo J Purviance H Safran, Curr Oncol Rep 2006 8 3 174 182 10.1007/s11912-006-0017-5 16618381
12. Adjuvant radiotherapy and radiochemotherapy in the management of esophageal cancer: a review of the literature. M Carcaterrra MF Osti V De Sanctis C Caruso F Berardi RM Enrici, Rays 2005 30 4 319 322 16792007 (Pubitemid 43938425)
13. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. D Bottke D Koychev A Busse K Heufelder T Wiegel E Thiel W Hinkelbein U Keilholz, Radiat Res 2008 170 1 41 48 10.1667/RR0986.1 18582150
14. Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. T Shimokuni K Tanimoto K Hiyama K Otani M Ohtaki J Hihara K Yoshida T Noguchi K Kawahara S Natsugoe, Int J Oncol 2006 28 5 1153 1162 16596231
15. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. X Song X Liu W Chi Y Liu L Wei X Wang J Yu, Cancer Chemother Pharmacol 2006 58 6 776 784 10.1007/s00280-006-0224-7 16532342
16. The Gray Lecture 2001: coming technical advances in radiation oncology. H Suit, Int J Radiat Oncol Biol Phys 2002 53 4 798 809 12095545 (Pubitemid 34722624)
17. Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. K Ogawa T Utsunomiya K Mimori F Tanaka N Haraguchi H Inoue S Murayama M Mori, Int J Oncol 2006 28 3 705 713 16465376
18. A global perspective of radiation-induced signal transduction pathways in cancer therapeutics. S Gupta MM Ahmed, Indian J Exp Biol 2004 42 12 1153 1176 15623227 (Pubitemid 39623423)
19. Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. KM Ahmed S Dong M Fan JJ Li, Mol Cancer Res 2006 4 12 945 955 10.1158/1541-7786.MCR-06-0291 17189385
20. Fractionated irradiation leads to restoration of drug sensitivity in MDR cells that correlates with down-regulation of P-gp and DNA-dependent protein kinase activity. JS Ryu JH Um CD Kang JH Bae DU Kim YJ Lee DW Kim BS Chung SH Kim, Radiat Res 2004 162 5 527 535 10.1667/RR3260 15624307
21. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. BT Hill E Moran C Etievant D Perrin A Masterson A Larkin RD Whelan, Anticancer Drugs 2000 11 3 193 200 10.1097/00001813-200003000-00007 10831278
22. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. D Nielsen C Maare J Eriksen T Litman T Skovsgaard, Int J Radiat Oncol Biol Phys 2001 51 4 1050 1057 11704330 (Pubitemid 33026437)
23. Platinum resistance: the role of DNA repair pathways. LP Martin TC Hamilton RJ Schilder, Clin Cancer Res 2008 14 5 1291 1295 10.1158/1078-0432.CCR- 07-2238 18316546
24. How do real tumors become resistant to cisplatin? P Borst S Rottenberg J Jonkers, Cell Cycle 2008 7 10 1353 1359 18418074 (Pubitemid 351872573)
25. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Y Watanabe M Koi H Hemmi H Hoshai K Noda, Br J Cancer 2001 85 7 1064 1069 10.1038/sj.bjc.6692037 11592780
26. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. X Lin SB Howell, Mol Cancer Ther 2006 5 5 1239 1247 10.1158/1535-7163.MCT-05-0491 16731756